BioPharma Resources

Drug Trial Radar · NCT06459180

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 686 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

686

Planned (sponsor's estimate)

Start

Jul 24, 2024

Primary completion

Jun 15, 2028

Study completion Jun 15, 2028

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
First posted
Jun 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the Phase 3 portion. The purpose of this study is to compare the efficacy and safety of sacituzumab tirumotecan versus treatment of physician's choice as second-line treatment for participants with recurrent or metastatic cervical cancer in the Phase 3 portion. The primary study hypotheses are that, in the Phase 3 portion, sacituzumab tirumotecan results in a superior overall survival compared to TPC in participants with high trophoblast cell surface antigen 2 (TROP2) expression level and in all participants.

Conditions

  • Cervical Cancer

Interventions

  • Sacituzumab TirumotecanBiological

    IV infusion

  • PemetrexedDrug

    IV infusion

  • Tisotumab VedotinBiological

    IV infusion

  • TopotecanDrug

    IV infusion

  • VinorelbineDrug

    IV infusion

  • GemcitabineDrug

    IV infusion

  • IrinotecanDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) in Sacituzumab Tirumotecan Run-inTime frame: Up to approximately 46 months
  2. Number of Participants Experiencing One or More Adverse Events (AEs) in Sacituzumab Tirumotecan Run-inTime frame: Up to approximately 46 months
  3. Number of Participants Discontinuing Study Treatment Due to an AE in Sacituzumab Tirumotecan Run-inTime frame: Up to approximately 46 months
  4. Overall Survival (OS) in Phase 3 PortionTime frame: Up to approximately 35 months

Locations

240 sites in 32 countries. Site status is shown where the registry gives one.

  • USA Mitchell Cancer Institute-Clinical Trials ( Site 4126)

    Mobile, Alabama

  • Providence Alaska Medical Center ( Site 4137)

    Anchorage, Alaska

  • HonorHealth (HH) ( Site 8002)

    Phoenix, Arizona

  • Arizona Oncology Associates - HOPE ( Site 8001)

    Tucson, Arizona

  • Moores Cancer Center-Clinical Trials Office - Gynecological Oncology ( Site 4125)

    La Jolla, California

  • UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc ( Site 4105)

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian ( Site 4104)

    Newport Beach, California

  • Mount Sinai Comprehensive Cancer Center ( Site 4143)

    Miami Beach, Florida

  • Advent Health ( Site 4140)

    Orlando, Florida

  • Florida Cancer Specialists East ( Site 7001)

    West Palm Beach, Florida

  • Northside Hospital ( Site 4127)

    Atlanta, Georgia

  • Georgia Cancer Center at Augusta University ( Site 4112)

    Augusta, Georgia

  • Lewis Cancer and Research Pavilion ( Site 4114)

    Savannah, Georgia

  • University Medical Center New Orleans ( Site 4132)

    New Orleans, Louisiana

  • Willis Knighton Medical Center ( Site 4101)

    Shreveport, Louisiana

  • The Center of Hope ( Site 4106)

    Reno, Nevada

  • Holy Name Medical Center ( Site 4117)

    Teaneck, New Jersey

  • Optimum Clinical Research Group ( Site 4138)

    Albuquerque, New Mexico

  • Perlmutter Cancer Center NYU Langone Hospital - Long Island ( Site 4145)

    Mineola, New York

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 4121)

    New York, New York

  • Duke Cancer Institute ( Site 4120)

    Durham, North Carolina

  • University of Cincinnati Medical Center ( Site 4128)

    Cincinnati, Ohio

  • The Ohio State University ( Site 4103)

    Hilliard, Ohio

  • Oklahoma Cancer Specialists and Research Institute, LLC-Clinical Research ( Site 4116)

    Tulsa, Oklahoma

  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007)

    Eugene, Oregon

  • Legacy Good Samaritan Medical Center-Oncology Clinical Research ( Site 4115)

    Portland, Oregon

  • Sidney Kimmel Cancer Center - Jefferson Health ( Site 4142)

    Philadelphia, Pennsylvania

  • Asplundh Cancer Pavilion ( Site 4113)

    Willow Grove, Pennsylvania

  • The West Clinic, PLLC dba West Cancer Center ( Site 4108)

    Germantown, Tennessee

  • Texas Oncology - Central/South Texas ( Site 8010)

    Austin, Texas

  • Texas Oncology - DFW ( Site 8003)

    Fort Worth, Texas

  • Houston Methodist Hospital OB/GYN ( Site 4102)

    Houston, Texas

  • Texas Oncology - San Antonio ( Site 8006)

    San Antonio, Texas

  • Texas Oncology - Northeast Texas ( Site 8009)

    Tyler, Texas

  • Texas Oncology - Gulf Coast ( Site 8008)

    Webster, Texas

  • University of Virginia Cancer Center ( Site 4123)

    Charlottesville, Virginia

  • Inova Schar Cancer Institute ( Site 4139)

    Fairfax, Virginia

  • Swedish Medical Center-Swedish Cancer Institute ( Site 4134)

    Seattle, Washington

  • Hospital Aleman-Oncology ( Site 0100)

    Buenos Aires, Argentina

  • Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0109)

    CABA, Argentina

Showing 40 of 240 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.